+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Looking Ahead to 2024 - the Future of Pharma?

  • PDF Icon

    Report

  • 54 Pages
  • May 2024
  • Region: Global
  • GlobalData
  • ID: 5976905
This report provides a summary of the near and long-term future of the pharmaceutical industry from the standpoint of drug development. It provides a high-level analysis of key trends and movements within the industry via regulatory, clinical, and market-based analysis, allowing you to discern the large-scale changes and how best to pivot and prioritize them within your sectors.

Scope

This 54-page report gives important, expert insight you won’t find in any other source. 25 figures throughout the report illustrate major points and trends in future pharmaceutical sales forecasts and company pipelines. This report is required reading for :
  • Investors that want to understand future trends impacting the biopharmaceutical industry as well as identifying companies to invest in
  • Companies that are interested in entering the biopharmaceutical space and where best to focus on
  • Large pharma companies with investment groups or BD teams looking to see which companies are predicted to lead the industry in the near and far future
  • Small and medium pharma who want to focus their drug portfolio on future trends and are looking for partnership opportunities

Reasons to Buy

  • Year Ahead Opportunities - looking ahead in 2024 using sales and regulatory analyses to identify events and trends that may be opportunities.
  • Year Ahead Threats -looking ahead in 2024 using sales forecasts and clinical analyses to identify events and trends that may pose a threat.
  • Future Opportunities - looking ahead to 5 years into the future, using sales forecasts and analyses to identify the opportunities in 2029 that can be exploited.
  • Clinical Trials - using clinical analyses to identify key areas within clinical trials that have begun or are planned for 2024.

Table of Contents

1 Year Ahead Opportunities
1.1 Top 10 Companies by Pharmaceutical Sales 2024 versus 2023
1.2 Top 10 Key Therapy Areas 2024 versus 2023
1.3 Top 10 Drugs 2024 Versus 2023
1.4 2024 Drug Launches
1.5 2024 PDUFA dates
1.6 Top 10 Targets in the Pipeline
2 Year Ahead Threats
2.1 Drug Patent Expirations
2.2 Post-Marketing Obligations
3 Future Opportunities
3.1 Risk-Adjusted Net Present Value
3.2 Sales Five Years from Now
4 Clinical Trials
4.1 Clinical Trials in 2024
4.2 Decentralized vs Centralized Clinical Trials
5 Key Findings
  • Appendix
6.1 Abbreviations
List of Tables
Table 1: Blockbuster drug launches in 2024
Table 2: Top 10 small molecules by sales with expected patent expiries 2024
Table 3: Top 10 Biologics by Sales with Expected Patent Expiries (2023-2025)
List of Figures
  • Top 10 Companies by Pharmaceutical Sales, 2024 vs. 2023
  • Top 10 Key Therapy Areas, 2024 vs. 2023
  • Top 10 Key Therapy Areas, 2024 vs. 2023
  • Top 10 Drugs, 2024 vs. 2023
  • Top 10 Biologic Drugs, 2024 vs. 2023
2024 PDUFA Dates
  • Top 10 companies with the most drugs in late-stage development
  • Top 10 biologic targets in development
  • Top 10 small molecule targets in development
  • Genomics identified as the top emerging pharmaceutical industry trend for 2024
  • Industry’s Growth During the Next 12 Months - Opinion Survey
  • Top 10 small molecules by sales with expected patent expiries 2024
  • Top 10 Biologics by Sales with Expected Patent Expiries (2023-2025)
  • PMOs by company, 2024
  • PMOs by drug, 2024
  • Top 10 drugs by 2024 by NPV
  • Top 10 companies by 2029 pharmaceutical sales
  • Percentage sales change 2024-29 for top 10 sales companies
  • Top 10 companies by 2029 biologic sales
  • Percentage sales change 2024-29 for top 10 companies by 2029 biologic sales
  • Small molecule versus biologic sales forecasts
  • mRNA versus genome editing sales forecasts
  • Clinical trials starting in 2024 by sponsor
  • Clinical trial completions by sponsor 2024
  • Clinical trials by entity type, 2024
  • Decentralized versus centralized clinical trials starting in 2024

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • GSK plc
  • Bristol-Myers Squibb Co
  • AstraZeneca Plc
  • Novartis AG
  • F. Hoffmann-La Roche Ltd
  • Merck & Co Inc
  • Johnson & Johnson
  • Sanofi
  • Pfizer Inc
  • AbbVie Inc
  • Eli Lilly and Co
  • Eisai Co Ltd
  • Anavex Life Sciences Corp
  • Vertex Pharmaceuticals Inc
  • Madrigal Pharmaceuticals Inc
  • Astellas Pharma Inc
  • Bayer AG
  • Biogen Inc
  • Mitsubishi Tanabe Pharma Corp
  • Takeda Pharmaceutical Co Ltd
  • UCB SA
  • Amgen Inc
  • Novo Nordisk AS
  • Lee's Pharmaceutical Holdings Ltd
  • Jiangsu Hengrui Medicine Co Ltd
  • Ipsen SA
  • Daiichi Sankyo
  • Regeneron
  • Vanda Pharma ,Basilea Pharma
  • Dachii Sankyo
  • Merck & Co